Episode
Intercepting Cancer When DNA Surveillance Fails
- Podcast
- The Bio Report
- Published
- Apr 8, 2026
- Duration seconds
- 2369
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/intercepting-cancer-when-dna-surveillance-fails/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-bio-report-1092382/intercepting-cancer-when-dna-surveillance-fails.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Many people with the genetic condition Lynch syndrome live with the near‑certainty that they will one day develop cancer and have few options beyond constant screening and, in some cases, preventive surgery. Nouscom is trying to change that by training the immune system to spot and destroy cancer cells before tumors ever form. We spoke to Marina Udier, CEO of Nouscom, about the company’s experimental cancer vaccines, how they work, and the broader potential for the company’s off‑the‑shelf cancer therapies.